Page 100 - Read Online

Laenger F. The challenge of NSCLC diagnosis and predictive lung cancer (NSCLC): ESMO clinical practice guidelines
analysis on small samples. Practical approach of a working for diagnosis, treatment and follow-up. Ann Oncol
group. Lung Cancer 2012;76:1-18. 2012;23:vii56-64.
3. Giaccone G. Epidermal growth factor receptor inhibitors 11. Scagliotti GV, Novello S, Rapetti S, Papotti M. Current
in the treatment of non-small-cell lung cancer. J Clin Oncol state-of-the-art therapy for advanced squamous cell lung
2005;23:3235-42. cancer. Am Soc Clin Oncol Educ Book 2013;2013:354-8.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, 12. Aggarwal C, Langer CJ. Older age, poor performance status
Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, and major comorbidities: how to treat high-risk patients
Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, with advanced non small cell lung cancer. Curr Opin Oncol
Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, 2012;24:130-6.
Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, 13. Giroux Leprieur E, Lavole A, Ruppert AM, Gounant V,
Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Wislez M, Cadranel J, Milleron B. Factors associated with
Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma long-term survival of patients with advanced non-small cell
kinase inhibition in non-small-cell lung cancer. N Engl J Med lung cancer. Respirology 2012;17:134-42.
2010;363:1693-703. 14. Leung EY, Scott HR, McMillan DC. Clinical utility of the
5. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, pretreatment Glasgow prognostic score in patients with
Moreira AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M. advanced inoperable non-small cell lung cancer. J Thorac
Clarifying the spectrum of driver oncogene mutations in Oncol 2012;7:655-62.
biomarker-verifıed squamous carcinoma of lung: lack of 15. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M,
EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Ramlau R, Vynnychenko I, Park K, Eberhardt WE,
Clin Cancer Res 2012;18:1167-76. de Marinis F, Heeger S, Goddemeier T, O’Byrne KJ,
6. Metro G, Crinò L. Novel molecular trends in the management Gatzemeier U. Prognostic factors in patients with advanced
of advanced non-small-cell lung cancer. Expert Rev Anticancer non-small cell lung cancer: data from the phase III FLEX
Ther 2012;12:729-32. study. Lung Cancer 2012;77:376-82.
7. Riess JW, Wakelee HA. Metastatic non-small cell lung cancer 16. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F,
management: novel targets and recent clinical advances. Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA
Clin Adv Hematol Oncol 2012;10:226-34. Jr. The impact of induction chemotherapy on the outcome of
8. Thatcher N, Hirsch FR, Szczesna A, Ciuleanu TE, second-line therapy with pemetrexed or docetaxel in patients with
Szafranski W, Dediu M, Ramlau R, Galiulin R, Bálint B, advanced non-small-cell lung cancer. Ann Oncol 2007;18:453-60.
Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, 17. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival
Paz-Ares L, Depenbrock H, Nanda S, Kruljac-Letunic A, of patients with advanced colorectal cancer improves
Socinski MA. A randomized, multicenter, open-label, phase with the availability of fl uorouracil-leucovorin, irinotecan,
III study of gemcitabine-cisplatin (GC) chemotherapy plus and oxaliplatin in the course of treatment. J Clin Oncol
necitumumab (IMC-11F8/LY3012211) versus GC alone in the 2004;22:1209-14.
fi rst-line treatment of patients (pts) with stage IV squamous
non-small cell lung cancer (sq-NSCLC). J Clin Oncol How to cite this article: Savini A, Berardi R, Mazzanti P,
2014;32:5s. Caramanti M, Santoni M, De Lisa M, Morgese F, Rinaldi S, Torniai M,
9. Pirker R. Epidermal growth factor receptor-directed Fiordoliva I, Onofri A, Cascinu S. Squamous cell carcinoma of the
monoclonal antibodies in nonsmall cell lung cancer: an update. lung: clinical criteria for treatment strategy. J Cancer Metastasis Treat
Curr Opin Oncol 2015;27:87-93. 2015;1:90-3.
10. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E; Received: 01-03-2015; Accepted: 13-05-2015.
ESMO Guidelines Working Group. Metastatic non-small-cell Source of Support: Nil, Confl ict of Interest: None declared.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 2 ¦ July 15, 2015 ¦ 93